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Table. Clinical staging and tumor characteristics of enrolled patients (N = 34)

1147981 ‐ The effect of lymphatic microsurgical preventive healing approach (LYMPHA) on the
development of upper‐extremity lymphedema following axillary lymph node dissection in breast cancer
patients
Omar Qutob, Sanjay Rama, Lisa Black, Michele Zubalik, Jessica Bensenhaver, Lindsay Petersen, Saul D.
Nathanson, Donna Tepper, Daniel Yoho, Maristella Evangelista, Dunya Atisha
Henry Ford Health System, Detroit, MI
Background/Objective: Lymphedema following axillary lymph node dissection (ALND) is a common
complication that can negatively impact quality of life as it reduces the functional capacity of the
affected arm. It can also predispose patients to serious infectious complications such as limb cellulitis
and development of malignancy. The lymphatic microsurgical preventive healing approach (LYMPHA
procedure) involves the creation of a lymphatic‐to‐venous bypass at the time of axillary lymph node
dissection (ALND) as a means of preventing lymphedema. The goal of our study is to assess the effect of
LYMPHA on the development of clinical and subjective post‐operative lymphedema.
Methods: This is a prospective longitudinal study in patients with breast cancer who underwent ALND
with or without LYMPHA. The incidence of lymphedema was compared between ALND alone and ALND
with LYMPHA using descriptive statistics. Limb circumference of both affected and unaffected limbs
were measured and used to calculate limb volume by using an equation that converts limb
circumference (cm) to volume (cc). Lymphedema was defined as a volume difference of ≥10% between
the affected and unaffected limb. Patient symptoms were also assessed and compared between the 2
groups. Patient demographics including age, preoperative body mass index (BMI), smoking history,
comorbidities, receipt of neoadjuvant or adjuvant chemotherapy, and receipt of adjuvant radiation were
compared between the groups.
Results: In our cohort of 139 patients, 104 underwent ALND with LYMPHA, while 35 underwent ALND
alone. Of these, 52.5% of patients had documented interlimb circumference measurements. The mean
age was 52.6 years old, mean BMI was 30.16 kg/m2, 4 patients (2.9%) had pre‐operative radiation, 102
patients (73.4 %) had post‐operative radiation, 86 patients (61.9 %) had neoadjuvant chemotherapy,
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and 58 patients (41.7 %) had adjuvant chemotherapy. There were no significant differences between the
2 groups in the above demographics and treatment variables, except those who underwent ALND alone
had a significantly higher incidence of diabetes mellitus (25.7% patients with ALND alone vs 11.5%
LYMPHA patients (p=0.043)). Based on patient reported symptoms and the need to initiate complete
decongestive therapy, 57.1% (n=20) of patients who underwent ALND alone developed lymphedema
compared to 26.9% (n=28 patients) of those who had ALND with LYMPHA (p=0.0011). When comparing
the relative volume difference, 57.1% (n=8) of ALND alone patients developed lymphedema versus
20.3% (n=12) of LYMPHA patients (p=0.0055).
Conclusions: Our data support the universal use of LYMPHA at the time of ALND as a means of
preventing upper extremity lymphedema. Further studies are needed to evaluate quality of life and
functional differences between those who had LYMPHA and those who did not.
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Background/Objective: In the evaluation of breast cancer, fine needle aspiration (FNA) of
sonographically suspicious axillary lymph nodes is helpful to clinically stage patients and guide
consideration of neoadjuvant therapy. However, data are limited on pathology findings at definitive
surgery in lymph nodes that are suspicious on axillary ultrasound (AUS) but FNA‐negative. The primary
objective of this study is to compare the frequency of SLN positivity between patients with negative AUS
versus patients with suspicious AUS but negative FNA.
Methods: With IRB approval, we identified a consecutive series of clinically node‐negative (cN0) patients
with invasive breast cancer treated with upfront surgery at our tertiary care center between 2016‐2021.
A prospectively collected clinical registry data source was utilized, with additional retrospective review
of medical records for clinical and pathologic features. Groups were compared using chi‐square tests for
nominal variables and Wilcoxon rank‐sum tests for ordinal and continuous variables.
Results: A total of 1,668 cN0 patients with invasive breast cancer were analyzed, including 341 with a
suspicious AUS and negative FNA (FNAneg group) and 1,327 with negative AUS and no FNA performed
(AUSneg group). The FNAneg group was younger (median 60 vs 65 years, p<0.001), had a higher cT stage
(27.3% vs 18.7% with cT2‐cT4 disease, p=0.001), and were more likely to have non‐luminal biologic
subtype (9.7% HER2+ and 7.0% TNBC vs 6.0% HER2+ and 5.1% TNBC, p=0.02). AUSneg patients were
more likely to have no surgical axillary staging (12.4%) compared to FNAneg patients (7.6%, p=0.01).
Among the 1477 with surgical axillary staging, the number of sentinel lymph nodes (SLNs) removed and
identified pathologically were significantly higher in FNAneg vs AUSneg patients (mean 2.4 vs 2.2,
p=0.002, and mean 2.8 vs 2.6, p=0.006) (see Table). Final axillary pathologic node positivity did not differ
significantly between the FNAneg and AUSneg groups (18.7% vs 15.9%, p=0.23), nor did the number of
SLNs positive, SLN metastasis size, likelihood of axillary dissection and associated additional disease, and
final pathology N category. Among FNAneg patients, 59/341 (17.3%) had a clip placed, with clipped node
retrieved in 27/59 (45.8%), not retrieved in 10/59 (16.9%), and retrieval unknown in 22/59 (37.3%). A
total of 26/27 retrieved clipped nodes were also SLNs (hot +/‐ blue), and 7/27 (25.9%) were positive
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